Obigen Pharma Inc. (TPEX:7876)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
37.40
+0.40 (1.08%)
At close: Feb 26, 2026
Market Cap 4.00B
Revenue (ttm) n/a
Net Income (ttm) -278.20M
Shares Out 106.92M
EPS (ttm) -2.62
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 123,329
Average Volume 142,438
Open 37.35
Previous Close 37.00
Day's Range 36.65 - 37.50
52-Week Range 34.55 - 69.00
Beta n/a
RSI 49.33
Earnings Date n/a

About Obigen Pharma

Obigen Pharma Inc. engages in research, manufacturing, and promotion of biotechnology and novel botulinum toxin. Preparations in Taiwan. Its lead product OBI-858, a 760 kDa novel toxin protein which fermented and purified from clostridium botulinum type A bacteria, which is in Phase II clinical trial. The company was founded in 2020 and is based in Zhubei, Taiwan. [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2020
Employees 57
Stock Exchange Taipei Exchange
Ticker Symbol 7876
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.